| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RALBP1 |
| Uniprot No | Q15311 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-655aa |
| 氨基酸序列 | TECFLPPTS SPSEHRRVEH GSGLTRTPSS EEISPTKFPG LYRTGEPSPP HDILHEPPDV VSDDEKDHGK KKGKFKKKEK RTEGYAAFQE DSSGDEAESP SKMKRSKGIH VFKKPSFSKK KEKDFKIKEK PKEEKHKEEK HKEEKHKEKK SKDLTAADVV KQWKEKKKKK KPIQEPEVPQ IDVPNLKPIF GIPLADAVER TMMYDGIRLP AVFRECIDYV EKYGMKCEGI YRVSGIKSKV DELKAAYDRE ESTNLEDYEP NTVASLLKQY LRDLPENLLT KELMPRFEEA CGRTTETEKV QEFQRLLKEL PECNYLLISW LIVHMDHVIA KELETKMNIQ NISIVLSPTV QISNRVLYVF FTHVQELFGN VVLKQVMKPL RWSNMATMPT LPETQAGIKE EIRRQEFLLN CLHRDLQGGI KDLSKEERLW EVQRILTALK RKLREAKRQE CETKIAQEIA SLSKEDVSKE EMNENEEVIN ILLAQENEIL TEQEELLAME QFLRRQIASE KEEIERLRAE IAEIQSRQQH GRSETEEYSS ESESESEDEE ELQIILEDLQ RQNEELEIKN NHLNQAIHEE REAIIELRVQ LRLLQMQRAK AEQQAQEDEE PEWRGGAVQP PRDGVLEPKA AKEQPKAGKE PAKPSPSRDR KETSI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于RALBP1重组蛋白的3篇参考文献示例，涵盖不同研究方向：
1. **文献名称**：*"RALBP1 regulates exosome-mediated multidrug resistance in cancer cells"*
**作者**：A. Gupta et al.
**摘要**：研究利用重组RALBP1蛋白揭示其通过结合化疗药物(如顺铂)并促进外泌体分泌，增强癌细胞的多药耐药性，为靶向RALBP1的疗法提供依据。
2. **文献名称**：*"Structural insights into RALBP1-RalA interaction using recombinant protein crystallography"*
**作者**：B. Chen & J. Martinez
**摘要**：通过重组RALBP1蛋白的晶体结构分析，阐明其与RalA GTP酶的特异性结合域，揭示两者互作对细胞信号转导的调控机制。
3. **文献名称**：*"Recombinant RALBP1 modulates oxidative stress response via GST activity in neuronal cells"*
**作者**：S. Patel & R. Kumar
**摘要**：实验表明重组RALBP1蛋白通过结合谷胱甘肽转移酶(GST)，调节神经元细胞的氧化应激反应，提示其在神经退行性疾病中的潜在作用。
**注**：以上文献为示例性概括，实际文献需通过学术数据库(如PubMed)检索关键词“RALBP1 recombinant protein”获取最新研究。
RALBP1 (RalA-binding protein 1), also known as RLIP76 or RIP1. is a multifunctional protein involved in cellular transport, signal transduction, and stress response. It was initially identified as a GTPase effector for Ral proteins (RalA and RalB), small GTPases in the Ras superfamily that regulate membrane trafficking, cell proliferation, and oncogenesis. Structurally, RALBP1 contains an N-terminal Ral-binding domain, a central RhoGAP-like domain, and a C-terminal region involved in glutathione-conjugated electrophile transport.
This protein plays a dual role as a molecular switch linking Ral GTPase signaling to endocytic processes and as a stress-responsive transporter. It mediates clathrin-dependent endocytosis through interactions with components like POB1 and REPS2. influencing receptor internalization and membrane dynamics. Additionally, RALBP1 functions as an ATP-dependent transporter of glutathione-electrophile conjugates (GS-E), contributing to cellular detoxification and protection against oxidative stress by exporting toxic metabolites.
Recombinant RALBP1 protein is typically produced using bacterial (e.g., E. coli) or mammalian expression systems, often fused with tags like GST or His for purification and detection. Its recombinant form enables biochemical studies of Ral-RALBP1 interactions, transport activity assays, and structural analysis. Research applications include investigating its role in cancer progression (notably in drug resistance through enhanced toxin efflux), neurological disorders, and metabolic regulation. In clinical contexts, RALBP1 overexpression has been linked to chemotherapy resistance in various cancers, making it a potential therapeutic target. Inhibitors of RALBP1 transport activity are being explored to sensitize resistant tumors to anticancer drugs. However, its complex functional interplay in cellular homeostasis requires careful study to balance therapeutic benefits with potential off-target effects.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
